Mesenchymal stromal cells administration for osteonecrosis of the jaw caused by bisphosphonate: report of two cases

Acta Oncol. 2020 Jul;59(7):789-792. doi: 10.1080/0284186X.2020.1730004. Epub 2020 Feb 20.

Authors

Gil Cunha De Santis¹, Leandro Dorigan de Macedo², Maristela Delgado Orellana¹, Lara Maria Alencar Ramos Innocentini², Tatiane Cristina Ferrari², Hilton Marcos Alves Ricz², Sâmia Rigotto Caruso¹, Taísa Risque Fernandes¹, Dimas Tadeu Covas^{1

3}

Affiliations

¹ Center for Cell-Based Therapy of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
² Dentistry and Stomatology Division, Hospital das Clínicas de Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
³ Internal Medicine, Ribeirão Preto School of Medicine, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.

PMID: 32079438
DOI: 10.1080/0284186X.2020.1730004

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Bisphosphonate-Associated Osteonecrosis of the Jaw / diagnostic imaging
Bisphosphonate-Associated Osteonecrosis of the Jaw / etiology
Bisphosphonate-Associated Osteonecrosis of the Jaw / surgery*
Bone Density Conservation Agents / adverse effects
Bone Density Conservation Agents / therapeutic use
Breast Neoplasms / drug therapy
Female
Humans
Male
Mesenchymal Stem Cell Transplantation*
Multiple Myeloma / drug therapy
Zoledronic Acid / adverse effects
Zoledronic Acid / therapeutic use

Substances

Bone Density Conservation Agents
Zoledronic Acid